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Influence of long-term treatment with equine somatotropin
(EquiGen) on gonadal function in stallions with poor semen
quality
Abstract
The aim of the present study was to investigate the spermatogenic and Leydig cell activity in stallions
with impaired semen quality after treatment with equine somatotropin. Experiments were performed
using 18 adult clinically healthy stallions with poor semen quality which did not pass breeding
soundness evaluation. The animals were randomly divided into a treatment (n = 9) and a control (n = 9)
group. Over a period of 90 days, nine stallions received a daily intramuscular injection of 10 mg
recombinant equine somatotropin (EquiGen, BresaGen Limited, Adelaide, Australia) and 9 control
animals were injected with the same amount of physiological saline solution. During and until 2 months
after treatment, semen characteristics and daily sperm output as well as plasma testosterone
concentrations were determined monthly in all stallions. In addition, testosterone concentration
measurement after stimulation with hCG was performed in all animals immediately before and at the
end of the treatment period as well as 2 months later. Our results demonstrate that equine somatotropin
(EquiGen) given daily in a dose of 10 mg per animal during 90 days had no significant effect neither on
plasma testosterone concentrations and hCG-induced testosterone release nor on semen quality
parameters in adult stallions with poor semen characteristics.
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Summary 
The aim of the present study was to investigate the spermatogenic and Leydig cell activity 
in stallions with impaired semen quality after treatment with equine somatotropin. 
Experiments were performed using 18 adult clinically healthy stallions with poor semen 
quality which did not pass breeding soundness evaluation. The animals were randomly 
divided into a treatment (n=9) and a control (n=9) group. Over a period of 90 days, nine 
stallions received a daily intramuscular injection of 10 mg recombinant equine 
somatotropin (EquiGen®, BresaGen Limited, Adelaide, Australia) and 9 control animals 
were injected with the same amount of physiological saline solution. During and until 2 
months after treatment, semen characteristics and daily sperm output as well as plasma 
testosterone concentrations were determined monthly in all stallions. In addition, 
testosterone concentration measurement after stimulation with hCG was performed in all 
animals immediately before and at the end of the treatment period as well as 2 months 
later. Our results demonstrate that equine somatotropin (EquiGen®) given daily in a dose of 
10 mg per animal during 90 days had no significant effect neither on plasma testosterone 
concentrations and hCG-induced testosterone release nor on semen quality parameters in 
adult stallions with poor semen characteristics. 
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Einfluss einer Langzeitbehandlung mit equinem Somatotropin (EquiGen®) 
auf die Hodenfunktion von Hengsten mit schlechter Samenqualität 
 
Ziel der vorliegenden Arbeit war es, die Wirkung von equinem Somatotropin auf die 
Spermatogenese und Leydig-Zell Aktivität bei Hengsten mir reduzierter Samenqualität 
abzuklären. Für die Untersuchungen standen 18 adulte, klinisch gesunde Hengste vom 
Nationalgestüt in Avenches zur Verfügung, welche aufgrund ungenügender Samenqualität 
als nicht zuchttauglich eingestuft worden waren. Die Tiere wurden zufällig einer 
Behandlungs- (n=9) und Kontrollgruppe (n=9) zugewiesen. Neun Hengste erhielten 
täglich, während einer Dauer von 90 Tagen, 10 mg recombinantes equines Somatotropin 
(EquiGen®, BresaGen Limited, Adelaide, Australia) i.m. injiziert während den 9 
Kontrolltieren die entsprechende Menge physiologische Kochsalzlösung verabreicht 
wurde. Während und bis 2 Monaten nach Ende der Behandlung wurde monatlich bei allen 
Hengsten die Samenqualität beurteilt sowie die tägliche Spermienproduktion und die 
Plasmakonzentration von Testosteron bestimmt. Zusätzlich wurde bei allen Tieren 
unmittelbar vor und nach Ende der Behandlung sowie 2 Monate später eine Stimulation 
mit hCG vorgenommen. Aufgrund unserer Ergebnisse kann gefolgert werden, dass die 
tägliche Verabreichung von 10 mg equinem Somatotropin (EquiGen®) während 90 Tagen 
weder die Samenqualität noch die Plasmakonzentrationen von Testosteron ohne und nach 
hCG-Stimulation bei Hengsten mit schlechter Samenqualität signifikant beeinflusst hat. 
 
Schlüsselwörter: Hengst, Somatotropin, Samenqualität, Testosteron 
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Influence de la somatotropine équine recombinante (EquiGen®) sur la qualité 
de la semence et la sécrétion de testostérone chez l’étalon 
 
Chez l’étalon, l’influence de l’hormone de croissance sur la régulation des fonctions 
reproductives est encore peu connue. Le but de cette étude était d’examiner l’activité des 
cellules germinales et de Leydig chez l’étalon après un traitement avec de la somatotropine 
équine. L’expérience a été effectuée sur 18 étalons du Haras National d’Avenches qui 
n’ont pas passé l’examen de la fonction génitale a cause d’une mauvaise qualité de la 
semence. Les animaux ont été répartis au hasard en un groupe de traitement (n=9) et un 
groupe de contrôle (n=9). Pendant une période de 90 jours, neuf étalons ont reçu une 
injection intramusculaire quotidienne de 10 mg de somatotropine équine recombinante 
(EquiGen®, BresaGen Limited, Adelaide, Australie) alors que les neuf animaux de contrôle 
ont reçu, de manière similaire, la même quantité d’une solution physiologique saline. 
Pendant et jusqu’à 2 mois après le traitement, la qualité de la semence et le nombre total de 
spermatozoïdes produit par jour, ainsi que la concentration de testostérone plasmatique ont 
été déterminés chez tous les étalons. De plus, des mesures de la concentration de 
testostérone après stimulation à l’hCG ont été effectuées chez tous les animaux 
immédiatement avant et à la fin de la période de traitement, ainsi que 2 mois plus tard. Nos 
résultats démontrent que l’administration de somatotropine équine recombinante n’a 
d’effets significatifs ni sur les caractéristiques qualitatives de la semence, ni sur la 
concentration de testostérone plasmatique et sur la sécrétion de testostérone induite par le 
test hCG. 
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Introduction 
Somatotropin (ST) is a growth hormone (GH) released by the anterior pituitary gland that 
is essential for normal skeletal development. In recent years, accumulated clinical and 
laboratory evidence suggests that ST also plays an important role in the reproductive 
system by influencing gonadal development in young animals and maintaining normal 
reproductive function in adult animals. GH receptors have not only been detected in the 
ovary of various species (Mathews et al., 1989; Lobie et al., 1990; Schams and Berisha, 
2004) but also in the male reproductive system including Leydig and Sertoli cells, the vas 
deferens, the prostate gland, the ductus epididymis and the seminal vesicles (Lobie et al., 
1990; N’Diaye et al., 2002). Moreover, delayed puberty has been observed in human 
patients with GH deficiency or GH resistance, and subjects with GH excess as in 
acromegaly have been known to be infertile (Codner and Cassorla, 2002). Early studies on 
rats indicated an apparent association of GH-deficiency with both compromised 
spermatogenesis and impaired sperm motility (Breier et al., 1996; Gravance et al., 1997). 
Furthermore, treatment of subfertile male GH-deficient rats with recombinant bovine GH, 
markedly increased sperm motility as well as plasma concentration of insulin-like growth 
factor-I (IGF-I). IGF-I is synthesized in the liver as well as in the gonads and is directly 
stimulated by GH (Breier et al., 1996). A recent review (Chandrashekar et al., 2004) 
reports the presence of IGF-I receptors in the gonads of both male and female, providing 
further evidence of GH influence on gonadal activity. Finally in clinical trials in subfertile 
men, sperm motility during GH treatment was significantly increased (Ovesen et al., 1996) 
whereas in another study GH therapy had no effect in men with idiopathic oligozoospermia 
(Lee et al., 1995). 
Experimental use of GH in order to increase gonadal function has provided promising 
results in both female and male animals. In the cow, treatment with recombinant bovine 
somatotropin (bST) has been shown not only to improve oocyte morphology (Roth et al., 
2002) but also to enhance fertility in artificially inseminated cows (Santos et al., 2004). 
Furthermore, the application of bST increased the percentage of transferable embryos in 
superovulated cows and improved pregnancy rates after embryo transfer (Moreira et al., 
2002). In the mature bull, treatment with bST increased the ejaculate volume (Bousquet et 
al., 2004), sperm motility after freezing/thawing and the non-return rate after artificial 
insemination (Sauerwein et al., 2000). 
 
 
5
Studies concerning the use of GH in the equine species have shown controversial results. 
Similarly to GH treatment in the cow, administration of equine somatotropin (eST) to 
cyclic mares significantly increased the number of small follicles on the ovaries (Cochran 
et al., 1999). In the stallion, treatment with the somatostatin analogue octreotid resulted in 
a transient decrease in semen motility and testosterone release after hCG-stimulation 
(Aurich et al., 2003). Storer et al. (2005) reported that daily administration of recombinant 
equine GH at 20µg/kg body weight over 21 days increased plasma IGF-I concentrations 
but had no effect on blood LH, FSH and testosterone concentrations. GH-treated stallions 
showed higher ejaculate volume, but motility, total sperm and sperm morphology in 
ejaculates collected 2 months after initiation of the GH treatment were not affected. 
Nonetheless higher pregnancy rates were observed in mares when bred with stallions 
showing greater concentrations of IGF-I in seminal plasma, suggesting a positive IGF-I 
effect on sperm function (Macpherson et al., 2002). 
The aim of the present study was to investigate the spermatogenic and Leydig cell activity 
in adult stallions with poor semen quality after long-term treatment with recombinant 
equine somatotropin. 
 
Animals, Materials and Methods 
Animals 
The experiment was carried out using 18 adult clinically healthy warmblood stallions, aged 
between 7 and 24 years from the National Stud in Avenches (Switzerland). From earlier 
studies (Janett et al., 2003a; 2003b; 2005) all stallions were known to have poor semen 
quality and did not pass semen evaluation according to the guidelines of “Clinical Fertility 
Evaluation of the Stallion” by the Society for Theriogenology (Kenney et al., 1983). The 
animals were kept in box stalls bedded with straw and were fed hay or haylage, oats, 
barley, corn and pellets supplemented with minerals. Water was available at libitum. All 
animals were exercised daily for at least 1 hour. 
 
Experimental design 
Before the onset of the experiment, the stallions were trained to mount the phantom and 
randomly allocated to a GH treatment (n=9) and a control group (n=9) with similar age 
distribution. GH treated animals were given 10 mg per day (≈ 20 µg/kg body weight) of 
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recombinant equine somatotropin (EquiGen®, BresaGen Ltd., Adelaide, Australia) 
dissolved in 2 ml sterile water for injection and the control animals received an equivalent 
volume of saline solution. In both groups daily injections were applied intramuscularly 
during a period of 90 days starting in the month of July. During treatment the stallions 
were regularly examined by a veterinarian and adverse reactions caused by the injections 
were observed and registered. 
 
Semen collection and examination 
Immediately before, during and until 2 months after the treatment, ejaculates were 
collected at monthly intervals, for 7 consecutive days each time from July to December. 
Semen was evaluated on days 5, 6 and 7 of each monthly collection. Ejaculate volume of 
the gel-free semen was measured with a graduated cylinder. Total and progressive motility, 
sperm concentration and total sperm were assessed in freshly diluted (INRA 96, IMV, 
Aîgle, France) semen with a Sperm Analyzer (HTM-IVOS, Version 12, Beverly, MA, 
USA) using 20 micron standard count analysis chambers (Art. no. SC 20-01-C, Leja, 
Nieuw-Vennep, The Netherlands) and standardized threshold values for stallion semen. 
The monthly values for each semen parameter were calculated as mean of the collection 
days 5-7. The daily sperm output (DSA) was determined as mean of the total sperm from 
days 5-7 (Love et al., 1991). For morphological examination, five drops of fresh semen 
collected on day 6 were fixed in 2 mL Hancock solution and smears prepared. At least 200 
spermatozoa were subsequently evaluated by phase contrast microscopy (Olympus BX50, 
UplanF1 100x/1.30) and abnormal spermatozoa classified in major (acrosome defects, 
nuclear vacuoles, abnormal heads, loose abnormal heads, abnormal midpieces, proximal 
droplets) and minor (loose normal heads, abnormal tails, distal droplets) defects (Blom, 
1973; Jasko et al., 1990). 
 
Testosterone analysis and hCG-stimulation 
Blood samples (EDTA) for testosterone determination were collected monthly on day 7 of 
semen collection, between 8 and 9 am, by jugular venipuncture. In addition, an hCG-
stimulation was performed according to Cox (1989) on all stallions, before and at the end 
of the treatment period as well as 2 months later. Immediately after drawing the first blood 
sample, 6000 IU hCG (Chorulon®, Veterinaria AG, Zürich) were injected intravenously 
 
 
7
and 4 further blood samples were collected at intervals of 15 min. After collection the 
blood was centrifuged immediately (3000 x g, 10 min) and plasma decanted and stored at -
80°C until testosterone analysis. Testosterone was determined by 
electrochemiluminescence immunoassay (Elecsys 2010, Roche Diagnostics, Basel, 
Switzerland) as described earlier (Wang et al., 2004). The detection limit of the assay was 
0.02 ng/mL. All samples were analyzed using a biotinylated monoclonal antibody against 
testosterone. Cross-reactivity with estrogens and progesterone was < 0.01%, with 
androstendione 0.91% and with 5-α-dihydrotestosterone 1.89%. For validation of between 
assay precision a pooled samples were analyzed 6 times a day for a total of 10 days (n = 
60) and for within assay precision pooled samples were measured 20 times a day (n = 20). 
Inter- and intraassay coefficients of variation were 2.2% and 1.4%, respectively. 
 
Statistical analysis 
Data were analyzed using StatView 5.0 software program (SAS Institute, Wangen, 
Switzerland) and tested for normal distribution. A multivariate analysis of variance 
(ANOVA) with repeated measures was carried out to assess the effects of group allocation, 
time of collection and treatment (interaction between group and time) on semen 
characteristics and on plasma testosterone concentrations. Non-normally distributed values 
(acrosome defects, testosterone concentration) were logarithmized for this purpose. Group 
(EquiGen®, control) differences at individual time points were compared by unpaired 
student’s t-test in normally (volume, concentration, daily sperm output, total and 
progressive motility, normal sperm, major defects, nuclear vacuoles, abnormal heads) and 
by Mann-Whitney test in non-normally distributed variables. The level of statistical 
significance was assumed as P < 0.05. 
 
Results 
Plasma testosterone 
Results from ANOVA demonstrate that monthly measured plasma testosterone 
concentrations were significantly influenced by group (P = 0.0207) but neither by time of 
blood collection (P = 0.1429) nor by treatment (interaction between group and time, P = 
0.9568). 
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Mean monthly testosterone values of the EquiGen® group (range 0.32-0.89 ng/mL) were 
always higher during the whole experiment compared to control (range 0.26-0.42 ng/mL) 
stallions (Fig. 1). A significant (P < 0.05) group difference was only present in November. 
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Figure 1: Mean (± S.E.M.) plasma testosterone concentrations measured monthly in 9 
stallions with () and 9 stallions without () EquiGen®. *Significant difference between 
groups (P < 0.05, Mann-Whitney test). 
 
Plasma testosterone concentrations in response to hCG-stimulation evaluated by ANOVA 
showed a highly significant effect of hCG-application (P < 0.0001) with a significant 
group difference after stimulation (interaction between group and min after hCG, P = 
0.0011). There was no significant influence by group (P = 0.1932), single stimulation (P = 
0.4507) and treatment (interaction between group, single stimulation and min after hCG, P 
= 0.9568). 
Mean plasma testosterone concentrations in response to hCG stimulation performed 
before, and at the end of the treatment period and 2 months later are shown in Fig. 2. The 
stallions showed highly reproducible responses to intravenous injection of hCG, with 
testosterone concentrations increasing to mean values between 6.42-6.54 ng/mL at 60 min 
in stallions treated with EquiGen® and between 4.33-4.53 ng/mL in control animals. 
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Figure 2: Mean (± S.E.M.) plasma testosterone concentrations in response to hCG (6000 
IU) before (c), at the end of the treatment period (U) and 2 months later () in 9 stallions 
with (a) and 9 stallions without (b) EquiGen®. 
 
Semen quality 
Data of semen characteristics from ejaculates collected before, during and 2 months after 
the treatment analyzed by ANOVA are shown in Table 1. None of the parameters 
measured were significantly (P > 0.05) influenced either by group or by treatment 
(interaction between group and time of semen collection). However, the time of collection 
had a significant (P < 0.05) effect on volume, concentration, daily sperm output, normal 
spermatozoa, acrosome defects and abnormal heads in both groups. Changes of mean 
group values of these parameters during the whole study are shown in Fig. 3 and 4. A 
significant (P < 0.05) group difference in sperm concentration was present in September 
(Fig. 3b). 
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Table 1: Means (± S.E.M.) of semen characteristics from ejaculates collected from 9 
stallions with and 9 stallions without EquiGen® and the effect of group, time of semen 
collection and interaction between group and time. 
Parameter EquiGen® 
m ± S.E.M. 
Control 
m ± S.E.M. 
Group
P 
Time 
P 
Interaction
P 
Volume (mL) 28.9  ±  2.2 24.5  ±12.9 0.4455   0.0115* 0.1909 
Concentration (x 106/mL) 241.8  ±15.4 175.4  ±13.4 0.0907   0.0013* 0.4258 
Daily sperm output (x 109) 5.6  ±  0.3 3.8  ±  0.4 0.0922   0.0165* 0.8587 
Total motility (%) 75.1  ±  1.6 75.1  ±  1.5 0.9979 0.3323 0.9505 
Progressive motility (%) 50.5  ±  2.0 52.2  ±  2.1 0.7976 0.3103 0.9792 
Normal spermatozoa (%) 18.6  ±  2.4 22.2  ±  2.4 0.6687   0.0338* 0.2318 
Major sperm defects (%) 74.8  ±  2.7 70.5  ±  2.5 0.6375 0.0686 0.1007 
Acrosome defects (%) 16.0  ±  2.1 7.6  ±  1.1 0.1481   0.0093* 0.6691 
Nuclear vacuoles (%) 15.0  ±  1.6 17.8  ±  2.6 0.7096 0.0533 0.4929 
Abnormal heads (%) 33.7  ±  2.6 26.1  ±  2.1 0.3307   0.0308* 0.3975 
*Significant (P < 0.05) 
 
Adverse effects 
Adverse effects were observed in 6 of 9 stallions during the first month of EquiGen® 
treatment. The most prominent reactions were swelling at the injection site, apathy and 
pyrexia. Animals with elevated body temperature above 38.5°C were treated with 
vedaprofen (Quadrisol®, Intervet International BV, The Netherlands) a non steroidal anti-
inflammatory drug known to have no influence on semen quality (Janett et al., 2005). 
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Figure 3: Mean (± S.E.M.) volume (a), sperm concentration (b) and daily sperm output (c) 
in ejaculates collected monthly from 9 stallions with () and 9 stallions without () 
EquiGen® *Significant difference between groups (P < 0.05, unpaired student’s t-test) 
difference between groups. 
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Figure 4: Mean (± S.E.M.) percentage of normal sperm (a), acrosome defects (b) and 
abnormal heads (c) in ejaculates collected monthly from 9 stallions with () and 9 
stallions without () EquiGen®. 
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Discussion 
Results of our investigation demonstrate that 10 mg recombinant equine somatotropin 
(EquiGen®) administered once daily during 90 days did not significantly influence plasma 
testosterone concentrations or semen quality. A seasonal pattern of testosterone secretion, 
with lowest values during winter, as reported by others (Byers et al., 1983; Cox et al., 
1988; Clay and Clay, 1992; Inoue et al., 1992; Aurich et al., 2003) was not seen in our 
study. A seasonal effect of testosterone was also absent after hCG-stimulation, performed 
in July, October and December. These findings may be explained by the short 
experimental period of only 6 months lasting from midsummer (July) until early winter 
(December) and by the low sampling frequency for basal and stimulated testosterone 
concentrations. Based on episodic testosterone secretion in the stallion (Clay and Clay, 
1992; Byers et al., 1993) a seasonal pattern can not be identified by obtaining only single 
monthly values. Irrespective of treatment, the hCG-induced testosterone release after each 
stimulation differed not significantly. From these results it can be concluded that the daily 
injections of EquiGen® did not improve Leydig cell function either by increasing the cell 
number or their sensitivity for LH. This observation corresponds with the results of Storer 
et al. (2005) who demonstrated that daily intramuscular injections of 20 µg/kg body weight 
(an equivalent dose as used in our experiment) EquiGen® for 21 days in 5 stallions 
increased IGF-I concentrations but did not influence pituitary gonadotrope function or 
testosterone secretion. In contrast to the horse, the use of GH in rodents has been shown to 
stimulate testosterone secretion (Horikawa et al., 1989; Ohyama et al., 1995). 
In order to compare daily sperm output and semen quality over time, ejaculates were 
collected using a standardized protocol with depletion of extragonadal sperm reserves 
during 4 consecutive days followed by 3 further daily collections for determination of 
semen characteristics (Love et al., 1991). During the entire experimental period of 6 
months, some of the semen characteristics (volume, concentration, daily sperm output, 
normal sperm, acrosome defects, abnormal heads) showed significant variations in both 
groups over time. These differences in semen quality may be explained by a seasonal 
effect as shown in previous studies (Janett et al., 2003a; 2003b). An effect on semen 
quality parameters attributable to EquiGen®, however, was not obvious. Storer et al. (2005) 
also looked at testicular function in the stallion, and reported an increased ejaculate volume 
as the only measurable effect after EquiGen® application, with semen being collected 
every other day for 14 days beginning 2 months after initiation of the treatment. This 
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study, however, was carried out during the non breeding season and EquiGen® was given 
during 21 days only which makes a comparison with our data difficult. The lack of clear 
somatotropic action on gonadal function in the stallion is difficult to interpret and is 
supported by in vitro experiments showing that equine GH and humane recombinant IGF-I 
had no steroidogenic effect on Leydig cells (Hess and Roser, 2005). 
In the aged bull, subcutaneous treatment with 640 mg recombinant bovine GH every two 
weeks over 14 weeks was shown to have no effect on blood testosterone concentration. It 
did, however, increase sperm motility after freezing-thawing and non-return rate after 
artificial insemination (Sauerwein et al., 2000). The effect on sperm motility after freezing 
may be more attributable to GH induced changes in the spermatozoal environment, as a 
direct influence of GH on spermatogenesis could not be show in the bull (Santos et al., 
1999). This is in agreement with earlier reports where GH supplementation to prepubertal 
bulls (Hagen et al., 1991; MacDonald and Deaver, 1993) and boars (Swanlund et al., 1995) 
did not improve testicular development. In the young boar, however, daily treatment with 
porcine GH from 8 through 40 days of age promoted tubular and Sertoli cell maturation 
without any detectable change in plasma testosterone concentration (Swanlund et al., 
1995). From reports in humans (Laron, 1984) and animal models (McDonald and Deaver, 
1993; Ohyama et al., 1995; Swanlund et al., 1995; Breier et al., 1996; Gravance et al., 
1997) we can conclude that a beneficial effect of somatotropin on male reproductive 
performance is likely to be confined to prepubertal individuals or growth hormone 
deficient patients. 
Adverse effects with reactions including swelling and pain at the injection site as well as 
pyrexia were observed in 6 of 9 stallions given EquiGen® during the first month of 
treatment. To minimize side effects we recommend halving the dose (5mg/day) during the 
first week of treatment and to rotate the daily intramuscular injections between at least 4 
different injection sites. 
In summary it seems that long-term treatment with EquiGen® did not influence plasma 
testosterone concentrations nor semen quality in clinically healthy adult stallions with poor 
semen quality. 
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